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See Article, pages 913–919Wilson disease (WD) is a genetic disorder found worldwide. The
most common presentations are with liver disease or neuropsy-
chiatric disturbance. Although the primary defect is impaired bil-
iary copper excretion resulting in hepatic copper accumulation,
the liver is not always affected [1]. Presenting symptoms of liver
disease can be highly variable, ranging from asymptomatic, with
only biochemical abnormalities, to overt cirrhosis, with all its
complications, or acute liver failure associated with Coomb’s neg-
ative hemolytic anemia. On the other hand, patients with chronic
liver disease may not have any neurologic symptoms or brain
MRI abnormalities. Clinically evident liver disease may precede
neurologic manifestations by as much as 10 years. Wilson disease
may present symptomatically at any age, although the majority
present between ages 5 and 35.
The youngest patient reported with cirrhosis due to Wilson
disease was 3 years old [2]. About 3% of patients present beyond
the fourth decade, either as hepatic or neurologic disease [3]. The
oldest patients were two siblings diagnosed in their eighth dec-
ade [4,5]. WD can manifest with an impressive spectrum of neu-
rological, behavioral, or psychiatric disorders, which may be its
ﬁrst clinical manifestation, appearing simultaneously with hepa-
tic signs, or some years later. Neurological presentation can be
extremely subtle, and intermitted for many years, but may also
develop very rapidly leading to complete disability in a few
months.
The clinical hallmark of Wilson disease is the Kayser–Fleischer
ring, which is present in 95% of patients with neurologic symp-
toms but only in half of patients with Wilsonian liver disease
[6,7]. In children presenting with liver disease, Kayser–Fleischer
rings are usually absent [8].
The reasons for the highly variable clinical manifestations are
unknown. The so far reported disease modiﬁers are summarized
in Table 1. There is a wide range of mutations in the Wilson
disease (APT7B) gene, with most of the over 500 described
mutations being very rare. Not all mutations have the same path-
ophysiologic consequence at the cellular level. The most preva-
lent mutation in European patients is the H1069Q pointJournal of Hepatology 20
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disease patients in Europe) present more frequently at an older
age with neurologic symptoms [9]. A truncating mutation may
be associated with early onset of disease [10]. Beyond that, fur-
ther phenotype–genotype correlations were not found in dat-
abases with more than 1000 patients, possibly because all other
mutations are far less common. Environmental, epigenetic, and
other genetic factors may probably play a role. There is clear evi-
dence that female gender (mediated by estrogens) has an impact
on the course of disease. More than 2/3 of patients with fulmin-
ant Wilson disease are female and overall more females present
with hepatic disease than males [11].
Variations of some genes were reported to be linked to the
clinical presentation, like apolipoprotein E [12] or human prion
gene [13]. The data were obtained in small cohorts and some
were not reproduced by others. So far, the overall contribution
of other genetic factors to the disease heterogeneity is minimal.
This raises several important questions regarding the natural
history of Wilson disease and the long term management of
patients. In this issue of the Journal, a further association is
reported [14]. Gromadzka et al. genotyped the two 5,10-methyl-
enetetrahydrofolate reductase (one of the key folate/homocyste-
ine pathway enzymes) gene (MTHFR) polymorphisms: C677T and
A1298C in a relative small cohort (for the purpose of the study),
245 WD patients. Patients with the MTHFR 1298C allele were
4 years younger at symptoms onset than those without this
allele. Carriers of MTHFR ‘‘high activity’’ diplotype (double wild-
type homozygotes 677CC/1298AA) manifested WD at older age
than non-carriers (33.5 vs. 25.0 years, p = 0.0009). Patients with
the MTHFR 677T allele less frequently exhibited the neurological
WD phenotype (29.5% vs. 48.0%), and more frequently presented
with hepatic WD (41.9% vs. 29.3%), compared with subjects
MTHFR 677T().
Polymorphisms of 5,10-methylenetetrahydrofolate reductase
are linked to hundreds of diseases including coronary heart dis-
ease, colorectal cancer, acute lymphoblastic leukemia, cerebral
ischemia, inﬂammatory bowel diseases, schizophrenia, just to
name a few. Thus, the ﬁrst question is what are the underlying
mechanisms of all this disease associations? The authors argue
that homocysteine is involved in copper metabolism and is also
neurotoxic. This may well be the case, but multiple other11 vol. 55 j 753–755
Table 1. Disease modiﬁers in Wilson disease.
Effect [Ref.] 
Female gender  Fulminant WD: Female:male 2:1 11, 19 
ATP7B Mutations  
   H1069Q homozygotes Later onset, more neurologic disease 9, 20 
   Mutations in Exon 8 and 13 More hepatic disease 20 
   Truncating mutations Early onset hepatic disease 10 
COMMD1* mutations  Reduced stability of ATP7B, increased apoptosis, role in
human disease not established 
21 
Apolipoprotein E  Conflicting data, 4 in neurologic disease 12
13 Human prion gene 
⁄ COMMD1:copper metabolism Murr1 domain region 1. Murr1 is the gene responsible for the copper storage disease in Bedlington terriers.
Editorialconsequences have been described, including effects on DNA syn-
thesis or oxidative stress, common factors associated with cancer
development and chronic inﬂammation.
One key factor for increasing homocysteine levels is folate
intake. Unfortunately most of the studies, including the present
one, did not collect data on nutritional habits. As also addressed
by the authors, there is a geographic and ethnic variation in the
population frequency of the T allele. US Hispanics and Southern
Europeans have a high frequency of the variant allele (>40%),
whereas other European populations (e.g., British, Irish) and US
whites have frequencies between 30% and 36%. US blacks have
a low frequency of the variant allele (14%), while Asian popula-
tions have a frequency of 11% [15]. The fact that hepatic disease
at young age is more frequent in Asian population (with a low
frequency of MTHFR 677T) does not support the observation in
Polish patients.
There are many problems in the interpretation of genetic
association studies [16]. One of the basic requirements is to
deﬁne the phenotype as accurately as possible, ideally by some-
body not involved in the study. The authors correctly point out
the difﬁculty in deﬁning the time and type of symptomatic pre-
sentation. In clear cut cases, it is fairly straightforward to identify
patients with neurologic or hepatic symptoms.
However, if somebody presents with neurologic symptoms,
how can one exclude that the patient already had an asymptom-
atic liver disease for decades? If liver disease is accidentally found
at a routine blood test – how can one discard the possibility that
this patient would have developed the neurologic disease at a
later time? We described a case of an 18-year-old asymptomatic
woman with the accidental ﬁnding of a Kayser–Fleischer ring,
who received no treatment and developed neurologic symptoms
27 years later [3]. Many chronic liver diseases including chronic
viral hepatitis are asymptomatic and will be diagnosed when
the end stage liver disease produces symptoms. A delay in diag-
nosing WD for those patients with neuropsychiatric presenta-
tions is frequent and was in one case as long as 12 years [17].
Patients presenting with neuropsychiatric symptoms may have
concurrent symptomatic liver disease, but in most patients, liver
disease can only be detected by laboratory evaluation, imaging of
the liver, or liver biopsy. Some patients presenting with neuro-
logic symptoms report that they have previously experienced
transient episodes of jaundice, probably due to hemolysis [18].
About half of the patients have advanced ﬁbrosis or frank cirrho-
sis [1]. On the other hand, signs of liver disease may be even com-
pletely absent at biopsy [1].754 Journal of Hepatology 201Thus, the question is how one can deﬁne the phenotype. Obvi-
ously, diagnosis of liver disease is complex in asymptomatic
patients. Cirrhosis can be diagnosed quite reliably by noninvasive
techniques, while for milder forms, liver histology is still the
‘‘gold standard’’. The authors cite many reasons why they have
not done liver biopsies. This is acceptable for the clinical manage-
ment of patients, but in a study which compares neurologic with
hepatic presentation it is a necessity. Without a biopsy, the con-
clusion that thatMTHFR polymorphism contributes to the pheno-
typic variability of WD is not sustainable. The study should be
repeated in cooperation with centers where liver biopsies are
done routinely. Second, there is a major selection bias. The
authors work at a well recognized adult neuropsychiatric facility,
as a result the median age of their patients was 28 years. About
40% of patients with WD present below the age of 15 [11], thus,
apparently children and young adults with WD were not investi-
gated. If the association ofMTHFRmutations is valid, this group of
patients may have a low frequency of this ‘‘protective’’ mutation
and a statistical signiﬁcance may be lost. Finally, the study
included asymptomatic siblings; thereby the frequency of the
studied mutation may have been inﬂuenced.
In summary, the results of the study are not conclusive but
should encourage a worldwide cooperation to identify factors
associated with the phenotypic presentation in a sufﬁciently
large, well deﬁned group of WD patients. The difﬁculties to deﬁne
the phenotype in WD patients call for a study about the natural
history of WD.
Furthermore, MTHFR polymorphisms are common and have
been associated with many diseases. So the ﬁnding of an associ-
ation with WD phenotypes is neither unique nor speciﬁc.Conﬂict of interest
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